Why the latest JCEM publication matters for Soleno Therapeutics (SLNO) Soleno Therapeutics (SLNO) is back in focus after a ...
Please see the full Prescribing Information, including Medication Guide.
REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...
Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million. Preliminary unaudited fourth ...
Shares of Soleno Therapeutics (NASDAQ:SLNO) fell on Wednesday after a federal database indicated that a 17-year-old male treated with the company’s recently launched rare disease therapy Vykat XR had ...
About PWSPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates ...
About PWSPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates ...
Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most oversold biotech stocks to invest in. Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported third-quarter adjusted earnings of $0.47 per share ...
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback